Evidence-based modification of intratympanic gentamicin injections in patients with intractable vertigo.
OBJECTIVE
To compare the cochlear distribution of low-dose fluorescent gentamicin after intra-tympanic administration in guinea pig (GPs) with clinical data of low dose intra-tympanic gentamicin in patients with intractable vertigo.


METHODS
Purified gentamicin-Texas Red (GTTR) was injected intratympanically into GPs and the cochlear distribution and time course of GTTR fluorescence in outer hair cells (OHCs) was determined using confocal microscopy.


RESULTS
GTTR was rapidly taken up by OHCs, particularly in the subcuticular zone. GTTR was distributed in the cochlea in a decreasing baso-apical gradient, and was retained within OHCs without significant decrease in fluorescence until 4 weeks after injection.


CONCLUSIONS
OHCs rapidly take up GTTR after intra-tympanic administration with slow clearance.


METHODS
A modified low-dose titration intratympanic approach was applied to patients with intractable Ménière's Disease (MD) based on our animal data and the clinical outcome was followed. After the modified intratympanic injections for MD patients, vertigo control was achieved in 89% patients, with hearing deterioration identified in 16% patients. The 3-week interval titration injection technique thereby had a relatively high vertigo control rate with a low risk of hearing loss, and is a viable alternative to other intratympanic injection protocols.
Zhai
Feng
F
Department of Otology and Skull Base Surgery, Eye Ear Nose and Throat Hospital, Fudan University, Shanghai, China.
Liu
Jian-Ping
JP
Dai
Chun-Fu
CF
Wang
Qi
Q
Steyger
Peter S
PS
D000704:Analysis of Variance; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D001682:Biological Availability; D004432:Ear, Middle; D005839:Gentamicins / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006168:Guinea Pigs; D006801:Humans; D007267:Injections; D008575:Meniere Disease / Q000188:drug therapy; D018613:Microscopy, Confocal; D016896:Treatment Outcome; D014717:Vertigo / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D005839:Gentamicins
Laryngoscope. 2001 Aug;111(8):1343-57
11568567
Am J Otol. 1999 Mar;20(2):209-19
10100525
Am J Otolaryngol. 2001 Mar-Apr;22(2):111-5
11283825
Laryngoscope. 1996 Dec;106(12 Pt 1):1553-6
8948622
Acta Otolaryngol. 1991;111(6):1021-30
1763622
Am J Otolaryngol. 2007 Sep-Oct;28(5):289-93
17826528
Laryngoscope. 2007 Jul;117(7):1191-8
17603318
Otolaryngol Head Neck Surg. 2005 Dec;133(6):929-35
16360516
Acta Otolaryngol Suppl. 1997;526:54-7
9107358
Laryngoscope. 2004 Dec;114(12):2085-91
15564826
Laryngoscope. 2000 Aug;110(8):1298-305
10942130
Hear Res. 2001 Nov;161(1-2):10-22
11744276
C R Acad Sci III. 1993 Jul;316(7):682-7
8019890
Otol Neurotol. 2004 Jul;25(4):544-52
15241234
Acta Otolaryngol. 2001 Apr;121(3):336-41
11425197
Laryngoscope. 2003 May;113(5):815-20
12792316
J Assoc Res Otolaryngol. 2003 Dec;4(4):565-78
14605921
Otol Neurotol. 2001 Mar;22(2):210-4
11300271
Laryngoscope. 1997 Jan;107(1):49-55
9001265
Am J Otol. 1999 May;20(3):357-63
10337978
J Assoc Res Otolaryngol. 2004 Jun;5(2):144-52
15357417
Laryngoscope. 2004 Apr;114(4):694-7
15064626
Laryngoscope. 1997 Jan;107(1):83-9
9001270
Auris Nasus Larynx. 1997 Jul;24(3):239-46
9251852
Brain Res. 1995 Dec 15;704(1):135-40
8750975
Laryngoscope. 1996 Feb;106(2 Pt 1):225-30
8583859
J Assoc Res Otolaryngol. 2009 Jun;10(2):205-19
19255807
J Assoc Res Otolaryngol. 2003 Jun;4(2):176-95
12943372
J Otolaryngol. 1996 Feb;25(1):26-31
8816106
Hear Res. 2007 Aug;230(1-2):43-52
17616288
Brain Res. 1997 Nov 28;777(1-2):75-85
9449415
Acta Otolaryngol. 1992;112(2):272-7
1604991
J Assoc Res Otolaryngol. 2007 Dec;8(4):497-508
17899270
Otolaryngol Head Neck Surg. 1995 Sep;113(3):181-5
7675476